ARS Pharmaceuticals
SPRY
62 hedge funds and large institutions have $1.13B invested in ARS Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 62 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
70.26% more ownership
Funds ownership: 0% → 70.26% (+70%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$292M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$115M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$84.6M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$58.2M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
+$56M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MS
51
Maven Securities
St Helier,
Jersey
| $386K | +$278K | +8,333 | New |
|
52
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $232K | +$167K | +5,000 | New |
|
53
Ensign Peak Advisors
Salt Lake City,
Utah
| $232K | +$167K | +5,000 | New |
|
54
Norges Bank
Oslo,
Norway
| $232K | +$167K | +5,000 | New |
|
|
PHK
55
Point72 Hong Kong
Hong Kong
| $205K | +$148K | +4,422 | New |
|
56
Morgan Stanley
New York
| $110K | +$79K | +2,365 | New |
|
|
DKCM
57
Davidson Kempner Capital Management
New York
| $46K | +$33.4K | +1,000 | New |
|
58
Ohio Public Employees Retirement System (OPERS)
Columbus,
Ohio
| $12K | +$8.35K | +250 | New |
|
|
PA
59
Parallel Advisors
San Francisco,
California
| $8K | +$5.51K | +165 | New |
|
60
UBS Group
Zurich,
Switzerland
| $4K | +$3.11K | +93 | New |
|
|
SB
61
Samsara BioCapital
Palo Alto,
California
| $1.16K | +$835K | +25,000 | New |
|
62
Legal & General Group
London,
United Kingdom
| $1K | +$434 | +13 | New |
|
SPRY Hedge Fund Activity: Q4 2020 in Review
62 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q4 2020, worth a combined $1.13B.
Buyers outnumbered sellers: 62 funds opened new SPRY positions and 0 closed out — a net gain of 62 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $292M.
- 62 institutional investors held ARS Pharmaceuticals (SPRY) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $1.13B of ARS Pharmaceuticals stock for Q4 2020.
- 62 funds opened new ARS Pharmaceuticals positions in Q4 2020 and 0 closed out, a net change of +62 holders.
- The largest ARS Pharmaceuticals buyer in Q4 2020 was OrbiMed, an estimated $292M added.
Based on aggregated 13F filings for Q4 2020.